Bard antimicrobial Foley catheter marketing strategy includes risk-sharing offer.
This article was originally published in The Gray Sheet
Executive Summary
BARD ANTIMICROBIAL FOLEY CATHETER MARKETING STRATEGY INCLUDES RISK SHARING offer with hospitals. The catheter was cleared by FDA in August 1994 with the claim that it can "reduce urinary tract infections by as much as 70%," Bard President and CEO William Longfield said at the recent Alex. Brown & Sons Health Care seminar. Bard says it began marketing efforts for the device within the last month.